Entia
Medical devices that enable treatment from cancer patients' homes
- 21-100 employees
- Healthcare
- B2B
- Personal health
- Data Integration
- MedTech
- City of London, London, UK
Jump to section
Company mission
To reduce the burden of health conditions on patients and healthcare systems, making treatment more tolerable and less disruptive to everyday life.
Our take
Entia, a healthcare technology company specialising in remote patient monitoring, has developed a handheld blood-testing kit that allows chemotherapy patients to monitor their blood counts at home, helping clinicians tailor treatment to each individual's needs. The technology can reduce cancelled chemotherapy appointments and unnecessary hospital visits for routine blood tests, freeing up valuable treatment slots for other patients awaiting urgent care.
By supporting more personalised care and allowing patients to be monitored remotely, Entia's technology helps ensure that clinical pathways are shaped around individual needs while also offering the potential to significantly reduce healthcare costs.
Following a partnership with Pfizer UK and securing further funding, Entia has developed Entia Liberty, a virtual oncology solution. The company is now focused on making its virtual monitoring service available in the UK to patients with metastatic breast cancer, subject to the necessary regulatory approvals.
Freddie
Company Specialist at Welcome to the Jungle
Funding (last 2 of 5 rounds)
Jul 2023
$21.5m
SERIES A
Oct 2021
$12m
EARLY VC
Total funding: $37.4m
This company has top investors
Leadership
Toby Basey-Fisher
(Founder & CEO)Alongside Founding Entia and serving as the CEO, Toby is also an Honorary lecturer at Imperial College London, a role they have held since 2017.
Chris Burrows
(CTO)Chris joined Entia in 2015 as an Engineer, they then moved into the role of Head of Innovation in 2016 and then into the role of CTO in 2017.